Note: Ingredients listed on restricted chemical lists
EC/CAS
215-185-5/1310-73-2
Name of the chemical
sodium hydroxide
Concentration
95
General Information
Version
3.1
Revision date
2024-01-22
Product name
EMASORB II
1.2.1 Relevant identified uses
Professional use
Emergency telephone
+44 (0) 7990 767375
Icons in SDS
Company Information
company name
Elemental Microanalysis Ltd
e-mail address of the competent person responsible for the Safety Data Sheet
enquiries@microanalysis.co.uk
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H312, H314, H318
Hazard statements
Code
Statements
H312
Harmful in contact with skin
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
Harmful in contact with skin. Causes severe skin burns and eye damage. Causes serious eye damage.
2.2 Label elements
Labelling
Hazard pictograms
GHS05 GHS07
Signal word
Danger
Contains
Sodium hydroxide
Hazard statements
H312 - Harmful in contact with skin. H314 - Causes severe skin burns and eye damage.
Precautionary statements
P280 - Wear protective gloves/protective clothing/eye protection/face protection/hearing protection. P301+P330+P331+P310 - IF SWALLOWED: rinse mouth. Do NOT induce vomiting. Immediately call a POISON CENTER or doctor. P303+P361+P353+P310 - IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water/shower. Immediately call a POISON CENTER or doctor. P305+P351+P338+P310 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER or doctor. P312 - Call a POISON CENTRE or doctor if you feel unwell. P321 - Specific treatment (see supplemental first aid instruction on this label).
2.3 Other hazards
Contains no PBT and/or vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or substance(s) are not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %